Overview

A 10-gene lung NGS test is a focused next-generation sequencing panel interrogating ten cancer-predisposition and driver genes relevant to lung cancer risk assessment. As an in vitro diagnostic device, it sits at the intersection of two regulatory worlds: the laboratory-developed-test framework in some jurisdictions and the formal IVD framework in others. A distributor moving the product across borders must navigate both.

The regulatory clearance step is sometimes referred to colloquially as the hardest part of bringing an NGS product to market. The assay itself is complex, the bioinformatics pipeline is part of the device, and the regulatory evidence base must demonstrate both analytical validity and clinical utility.

Regulatory Pathways in Three Jurisdictions

In China, the National Medical Products Administration (NMPA) classifies NGS-based IVDs as Class III devices in most cases, requiring clinical trial evidence, a formal registration certificate, and post-market surveillance commitments. The review timeline is typically measured in months to years depending on the novelty of the assay and the prior literature.

In the European Union, the In Vitro Diagnostic Regulation (IVDR) replaced the IVDD in 2022 and tightens requirements substantially. A 10-gene lung NGS test is likely to fall into IVDR Class B or higher, requiring involvement of a notified body for conformity assessment. The technical file must include performance evaluation data, post-market performance follow-up plans, and a unique device identification system.

In the United States, the FDA regulates NGS-based IVDs through a variety of pathways including 510(k) clearance and De Novo classification, with companion diagnostic claims requiring a higher level of evidence. Many NGS tests for lung cancer are run as laboratory-developed tests under CLIA rather than as FDA-cleared kits, and the regulatory pathway for any cross-border shipment must be confirmed with counsel.

Practical Steps for Cross-Border Shipment

Before shipment, the distributor confirms the destination market's registration status of the specific kit version, not just of the platform. A change in primer set, software version, or intended use can reset the regulatory clock. The bill of lading must reflect the regulatory status and the kit's intended purpose.

Customs documentation typically includes the certificate of analysis, the registration certificate or 510(k) clearance letter where applicable, and a free-sale certificate from the country of origin. Local language labelling may be required at the time of release. Cold-chain integrity, where applicable, must be documented and verifiable on arrival.

Post-Market Surveillance and Drift

Regulatory frameworks evolve. A product cleared under one version of the rules can find its paperwork obsolete after a guidance update. Distributors must monitor regulator announcements for both the country of origin and the destination market, and they must be ready to update labelling or performance claims as guidance drifts.

FAQ

Q: Does a 510(k) clearance in the US automatically allow EU distribution? A: No. EU distribution requires CE marking under the IVDR, which is a separate conformity assessment process.

Q: What is the most common cause of customs delays for NGS kits? A: Documentation gaps — particularly missing or outdated certificates of free sale and registration certificates — are the most frequent cause of shipment holds.

Q: Is a laboratory-developed test exempt from IVD registration? A: In some jurisdictions LDTs enjoy limited exemptions, but cross-border shipment typically requires full registration regardless of the LDT status in the country of origin.

Q: How often must registration be renewed? A: Renewal cycles vary by jurisdiction. NMPA certificates are typically valid for five years, while CE certificates are valid for five years under IVDR, with annual surveillance audits by the notified body.